Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution
Vincenzo Di Noia, Fulvia Pimpinelli, Davide Renna, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 24, pp. 6815-6823
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis
Ainsley Ryan Yan Bin Lee, Shi Yin Wong, Louis Yi Ann Chai, et al.
BMJ (2022), pp. e068632-e068632
Open Access | Times Cited: 390
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Annika Fendler, Elisabeth G.E. de Vries, Corine H. GeurtsvanKessel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 6, pp. 385-401
Open Access | Times Cited: 176
Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review
Chiara Corti, Gabriele Antonarelli, Florian Scotté, et al.
Annals of Oncology (2021) Vol. 33, Iss. 2, pp. 158-168
Open Access | Times Cited: 70
Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers
Flaminia Campo, Aldo Venuti, Fulvia Pimpinelli, et al.
Vaccines (2021) Vol. 9, Iss. 10, pp. 1125-1125
Open Access | Times Cited: 42
Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events – a retrospective cohort study
Maximilian J. Mair, J.M. Berger, Manfred Mitterer, et al.
European Journal of Cancer (2022) Vol. 165, pp. 184-194
Open Access | Times Cited: 31
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study
Angioletta Lasagna, Federica Bergami, Daniele Lilleri, et al.
ESMO Open (2022) Vol. 7, Iss. 2, pp. 100458-100458
Open Access | Times Cited: 23
Determinants of humoral immune response to SARS-CoV-2 vaccines in solid cancer patients: A systematic review and meta-analysis
Durgesh Wankhede, Sandeep Grover, Paul Hofman
Vaccine (2023) Vol. 41, Iss. 11, pp. 1791-1798
Open Access | Times Cited: 12
Immunogenicity of SARS-CoV-2 vaccines in patients with cancer
Helen Kakkassery, Esme Carpenter, Piers Patten, et al.
Trends in Molecular Medicine (2022) Vol. 28, Iss. 12, pp. 1082-1099
Open Access | Times Cited: 18
Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis
Εfstathia Liatsou, Ioannis Ntanasis‐Stathopoulos, Stavros Lykos, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2266-2266
Open Access | Times Cited: 10
Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study
Yuki Katsuya, Tatsuya Yoshida, Atsuo Takashima, et al.
International Journal of Clinical Oncology (2024) Vol. 29, Iss. 4, pp. 386-397
Open Access | Times Cited: 2
Immune response of COVID-19 vaccines in solid cancer patients: A meta-analysis
Tiantian Hua, Rui Fan, Fan Yang, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 2
Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study
Wei Kang, Jessica J. P. Shami, Vincent Ka Chun Yan, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 13
Anti-SARS-COV-2 specific immunity in HIV immunological non-responders after mRNA-based COVID-19 vaccination
Marta Sisteré‐Oró, Naína Andrade, Diana D. J. Wortmann, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 13
COVID-19 and lung cancer: update on the latest screening, diagnosis, management and challenges
Simon Moubarak, Diala Merheb, Lynn Basbous, et al.
Journal of International Medical Research (2022) Vol. 50, Iss. 9
Open Access | Times Cited: 13
Rapid decline of humoral response to two doses of BNT162b2 vaccine in patients with solid cancer after six months: The urgent need of the additional dose!
Vincenzo Di Noia, Fulvia Pimpinelli, Davide Renna, et al.
European Journal of Cancer (2022) Vol. 165, pp. 169-173
Open Access | Times Cited: 11
Clinical efficacy of the first two doses of anti‐SARS‐CoV‐2 mRNA vaccines in solid cancer patients
Maria Silvia Cona, Agostino Riva, Davide Dalu, et al.
Cancer Medicine (2023) Vol. 12, Iss. 12, pp. 12967-12974
Open Access | Times Cited: 5
Potentiation of humoral response to the BNT162b2 vaccine after the third dose in patients with solid cancer
Vincenzo Di Noia, Fulvia Pimpinelli, Davide Renna, et al.
Annals of Oncology (2022) Vol. 33, Iss. 5, pp. 563-565
Open Access | Times Cited: 8
mRNA-COVID19 Vaccination Can Be Considered Safe and Tolerable for Frail Patients
Maria Teresa Lupo Stanghellini, Serena Di Cosimo, Massimo Costantini, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 8
Cancer Patients and the COVID-19 Vaccines: Considerations and Challenges
Muna Almasri, Khalifa Bshesh, Wafa Khan, et al.
Cancers (2022) Vol. 14, Iss. 22, pp. 5630-5630
Open Access | Times Cited: 8
Impaired immunogenicity after vaccination for SARS-CoV-2 in patients with gastrointestinal cancer: does tumor entity matter?
Malte B. Monin, Jens Gabriel Gorny, Moritz Berger, et al.
Journal of Gastrointestinal Oncology (2023) Vol. 14, Iss. 3, pp. 1218-1234
Open Access | Times Cited: 4
Predictors of poor serologic response to COVID-19 vaccine in patients with cancer: a systematic review and meta-analysis
Wenxing Yang, Dongxue Zhang, Zhuo Li, et al.
European Journal of Cancer (2022) Vol. 172, pp. 41-50
Open Access | Times Cited: 7
Seroconversion rate after COVID-19 vaccination in patients with solid cancer: A systematic review and meta-analysis
Juntao Yin, Yangyang Chen, Yang Li, et al.
Human Vaccines & Immunotherapeutics (2022) Vol. 18, Iss. 6
Open Access | Times Cited: 7
Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study
Enzo Maria Ruggeri, Fabrizio Nelli, Agnese Fabbri, et al.
ESMO Open (2021) Vol. 7, Iss. 1, pp. 100350-100350
Open Access | Times Cited: 9
Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study
Kei Nakashima, Masayuki Ishida, Hiroki Matsui, et al.
Human Vaccines & Immunotherapeutics (2022) Vol. 18, Iss. 6
Open Access | Times Cited: 6
Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment
Lara V. Donhauser, Julia Veloso de Oliveira, Cordula Schick, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 9, pp. e007387-e007387
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top